Complete response to anti-PD-1 antibodies occurs in 10–20% of patients with metastatic melanoma, and the majority of patients who receive anti-PD-1 antibodies for metastatic melanoma will ultimately develop resistance [41]. Here, PDCD1 is linked to metastatic melanoma.